A Study of ELND002 in Patients With Relapsing Forms of Multiple Sclero
An Open-Label, Long-Term, Follow-Up Study of Subcutaneous ELND002 in Patients With Relapsing Forms of Multiple Sclerosis
What it found
The trial ended early for another reason (see below).
This trial finished 13 years ago. We found no results in the registry or in any paper that cites it.
What was tested
Treatment tested
- ELND002
What it measured
Main measures
To determine the safety and tolerability of ELND002 including the identification of dose-limiting toxicity(ies) (DLT).
1 year
Safety
Other measures (1)
To evaluate the PK/PD/BM measurement of ELND002 in patients with MS.
1 year
How the body handles the medicine
Who could take part
Relapsing and progressive · 18 to 65
Show the full criteria
Inclusion criteria
* This study is open only to subjects who have completed the week 12 visit in study ELND002-MS103 while taking their assigned dose of study drug.
Exclusion criteria
* Subject has no new medical contraindications to continue participation in the study.
As registered. Criteria can change, so ask the trial team or your neurologist.
About this trial
In the sponsor's words
The purpose of this study is to evaluate the long-term safety and tolerability of ELND002 in patients with multiple sclerosis (MS) after participation in study MS103.
Papers
Loading reviews and guidelines…
History
Started
Dec 2010
Main results due
Dec 2012